Yale physicians using new technology to diagnose lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Yale Medicine physicians are using robotic bronchoscopy instead of traditional bronchoscopy for lung cancer diagnosis. Robotic bronchoscopy allows them to better reach smaller parts of the lungs. During a robotic bronchoscopy, the doctor uses a controller at a console to operate a robotic arm, which then guides the bronchoscope’s thin, flexible tube through the airways.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial. 
FDA has approved Hyrnuo (sevabertinib), an oral, reversible, tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login